Navigation Links
Study shows Hera Therapeutics experimental compound shuts down human papillomavirus that causes most cervical cancer
Date:8/22/2014

LA JOLLA, Cali., Aug. 22, 2014 /PRNewswire/ -- Research presented at the 29th Annual International Papillomavirus Conference shows that a therapy being developed by Hera Therapeutics Inc. combats three types of human papillomavirus, including the two that cause 70 percent of all cervical cancer.

When tested in several cultured human cell models, HTI-1968 blocked the replication of HPV-16, HPV-18 and HPV-11 cells, according to Louise T. Chow, Ph.D. and Thomas Broker, Ph.D., who presented the findings at the Seattle conference. The National Institute of Allergy and Infectious Diseases in the National Institutes of Health funded Chow's work at the University of Alabama, Birmingham.

"HTI-1968 is potent and selective, inhibiting the growth of these high-risk HPV types. Dr. Chow's findings, though early stage, offer hope to millions of women infected by one of these high-risk HPV types, including two that are responsible for 70 percent of cervical cancer cases," said Hera Therapeutics CEO Karl Hostetler, M.D.. Currently surgery is the only therapy available to women who have persistent infection with these types of HPV and show signs of abnormal cells.

Hera Therapeutics is developing a topical, non-surgical approach to treat HPV, which could alter the standard of care while preserving structural integrity of the cervix.

Approximately 96 million people worldwide, men and women, are infected with HPV-16 or HPV-18, according to the Centers for Disease Control. Almost 4,000 women in the U.S. die from invasive cervical cancer each year, according to the CDC.

While cervical cancer vaccines prevent infection from the disease, they are not approved by the FDA for marketing to people over 26-years-old and have not demonstrated efficacy in people already infected with the HPV virus.

About Hera Therapeutics Inc.

Using a new medicinal chemistry platform, Hera Therapeutics Inc. is focused on the research, development and commercialization of direct acting antivirals for infections with the human papillomavirus, herpes group viruses, HIV and animal retroviruses.

Hera Therapeutics was founded in 2012 by Karl Hostetler, M.D., a professor emeritus at University of California, San Diego, who was previously a founder of three biotech companies, including Chimerix, Triangle Pharmaceuticals and Vical.


'/>"/>
SOURCE Hera Therapeutics Inc.
Copyright©2014 PR Newswire.
All rights reserved

Related medicine technology :

1. Baxter Announces Positive Top-Line Results from Its Phase 3 Study of BAX 855, Extended Half-Life Recombinant FVIII for Hemophilia A Patients
2. Auxilium Pharmaceuticals, Inc. Announces Positive Data From Phase 2a Study Of CCH In Patients With Cellulite
3. Luoxis Announces Presentation of Positive Clinical Findings from Five-Year Clinical Study of Traumatic Brain Injury and Oxidation-Reduction Potential at 2014 American Academy of Surgical Trauma Meeting
4. Coherus Announces CHS-1420 (Investigational Adalimumab Biosimilar) Meets Primary Endpoint In Pivotal Pharmacokinetic Clinical Study
5. FDA Accepts CorMedix, Inc. Pivotal Phase 3 Study Protocol
6. TRU-D Tested in Most Comprehensive UV Disinfection Study to Date
7. Major Clinical Study Supports NIPT As First Line Screening Test For All Pregnant Women
8. R348 Did Not Meet Endpoints in Phase 2 Dry Eye Study
9. Study: 1 out of 5 adult orthopaedic trauma patients sought additional providers for narcotic prescriptions
10. Study Helps Medical Education Leaders Navigate the New Regulatory and Financial Landscape
11. BioSpecifics Technologies Corp. Announces Initiation of Phase 2 Clinical Study of CCH for Treatment of Lipoma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/14/2019)... ... February 14, 2019 , ... ... and Clark College Emeritus Professor of Education Gregory A. Smith speaks with Christopher ... emergence of Brand Ambassador programs, a new phenomenon in the marketing of educational ...
(Date:2/14/2019)... ... February 14, 2019 , ... ... a UroLift® Center of Excellence. The designation recognizes that Dr. Peterson has achieved ... a commitment to exemplary care for men suffering from symptoms associated with Benign ...
(Date:2/14/2019)... ... ... Neptune Society’s new location in Fort Worth, TX, is ready to open. ... Thursday, February 21, 2019. Members of the community can visit our new office, 6455 ... calling the office directly at (817) 838-5100. , The ribbon-cutting ceremony will begin at ...
Breaking Medicine Technology:
(Date:2/14/2019)... ... February 14, 2019 , ... At the ... of its Personal Cardiac Assistant (PCA 500), the only FDA-cleared, hospital quality, 12-lead ... can record single lead ECGs and identify arrhythmias, including atrial fibrillation or AFib. ...
(Date:2/13/2019)... BOARDMAN, Ohio (PRWEB) , ... February 13, 2019 , ... ... Best CBD Vape Juices for 2019 . The list is the result of ... company research. , Vaping is attractive to people who are looking for a ...
(Date:2/13/2019)... , ... February 13, 2019 , ... With Valentine’s Day ... transmitted disease (STD) testing service, is sharing 7 tips to ensure ‘Safe Sex’: ... if you’re going to engage in safe sex. Having clear, open, and honest communication ...
(Date:2/13/2019)... ... ... Castle announced today that it has raised $9.2M in Series A funding from ... First Round and F-Prime Capital Partners . Angel investors joining the round ... Networks, and Olivier Pomel, CEO at Datadog. This round brings the company’s total funding ...
(Date:2/13/2019)... , ... February 13, 2019 , ... A Place ... Choice Award from Home Care Pulse. The Employer of Choice Award is granted only ... Care Pulse, an independent satisfaction research firm for home care. A Place at Home ...
Breaking Medicine News(10 mins):